A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 282 participants.

Also called NCT05564039

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 282 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05564039
Other papers using this trial's data
  • Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial Annals of internal medicine, 2025-05 DOI, PubMed 40183678

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Germany, Mexico, Romania (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05564039. Randomized; no masking; primary purpose treatment. Start 2022-11-30 (actual); primary completion 2024-07-15 (actual). Results posted on 2025-08-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
Acronym
SURPASS-SWITCH
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Dulaglutide
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05564039
Content hash
6a6e2a06caff82de9386cf44a63463d483e3e94a13b1154e1da0a568efd267b9